FS118 Emerging Drug Insight and Market Forecast – 2035

FS118 Emerging Drug Insight and Market Forecast – 2035

“FS118 Emerging Drug Insight and Market Forecast – 2035” report provides comprehensive insights about FS118 for LAG-3 Next-generation Immunotherapies in the 7MM. A detailed picture of the FS118 for LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2035 is provided in this report along with a detailed description of the FS118 for LAG-3 Next-generation Immunotherapies. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FS118 market forecast, analysis for LAG-3 Next-generation Immunotherapies in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in LAG-3 Next-generation Immunotherapies.

Drug Summary

FS118 is a potentially first-in-class dual checkpoint inhibitor developed to overcome tumor evasion mechanisms promoted by two highly immunosuppressive pathways, LAG-3 and PD-L1. Despite the clinical progress made with PD-L1 therapies, the upregulation of other immune checkpoints in cancer, such as LAG-3, plays a vital role in promoting resistance to these drugs. Therapeutic antibodies that target the immune checkpoints (LAG-3) and PD-1 have shown increased clinical anti-tumor activity when given in combination. FS118 has shown in clinical trials and preclinical studies that it blocks both PD-L1 and LAG-3 simultaneously and has an additional mechanism of action to promote the shedding of LAG-3 from the surface of immune cells. Expanding the clinical development of FS118 into checkpoint-naive, biomarker-enriched NSCLC, and DLBCL patients will expand the clinical reach of this exciting LAG-3 and PD-L1 targeting bispecific antibody. This adds to the ongoing checkpoint inhibitor relapsed head and neck cancer study. Currently, the drug is in a Phase I/II trial in patients with advanced tumors to determine its efficacy in participants with squamous cell carcinoma of the head and neck (SCCHN).

In the Phase I clinical trial, FS118 was well tolerated, with no treatment-related serious adverse events and no dose-limiting toxicity up to 20 mg/kg. The Phase II proof-of-concept study in checkpoint inhibitor-relapsed head and neck cancer patients is ongoing.

As per the company presentation, it is anticipated that the initial data from the NSCLC CPI-naïve trial is expected to be released between H1 and H2 2023. In addition to that, initial data from the DLBCL CPI-naïve trial is expected to be released in H2 2023.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the FS118 description, mechanism of action, dosage and administration, research and development activities in LAG-3 Next-generation Immunotherapies.

Elaborated details on FS118 regulatory milestones and other development activities have been provided in this report.

The report also highlights the FS118 research and development activity in LAG-3 Next-generation Immunotherapies in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around FS118.

The report contains forecasted sales of FS118 for LAG-3 Next-generation Immunotherapies till 2035.

Comprehensive coverage of the late-stage emerging therapies for LAG-3 Next-generation Immunotherapies.

The report also features the SWOT analysis with analyst views for FS118 in LAG-3 Next-generation Immunotherapies.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FS118 Analytical Perspective by DelveInsight

In-depth FS118 Market Assessment

This report provides a detailed market assessment of FS118 in LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2027 to 2035.

FS118 Clinical Assessment

The report provides the clinical trials information of FS118 in LAG-3 Next-generation Immunotherapies covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for LAG-3 Next-generation Immunotherapies is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FS118 dominance.

Other emerging products for LAG-3 Next-generation Immunotherapies are expected to give tough market competition to FS118 and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FS118 in LAG-3 Next-generation Immunotherapies.

Our in-depth analysis of the forecasted sales data from 2027 to 2035 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FS118 in LAG-3 Next-generation Immunotherapies.

Key Questions

What is the product type, route of administration and mechanism of action of FS118?

What is the clinical trial status of the study related to FS118 in LAG-3 Next-generation Immunotherapies and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FS118 development?

What are the key designations that have been granted to FS118 for LAG-3 Next-generation Immunotherapies?

What is the forecasted market scenario of FS118 for LAG-3 Next-generation Immunotherapies?

What are the forecasted sales of FS118 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in LAG-3 Next-generation Immunotherapies and how are they giving competition to FS118 for LAG-3 Next-generation Immunotherapies?

Which are the late-stage emerging therapies under development for the treatment of LAG-3 Next-generation Immunotherapies?